However, in both mouse and human SCLC models (treatment naive or relapsed), the evaluation whether there is benefit from combining WEE1 inhibition with chemoimmunotherapy on tumor growth and on related to immune subsets will be a focus of future work. The gene discussed is WEE1; the disease is small cell lung carcinoma.